Menu
Currency
GWAS Study

Six Novel Loci Associated with Circulating VEGF Levels Identified by a Meta-analysis of Genome-Wide Association Studies.

Choi SH, Ruggiero D, Sorice R et al.

26910538 PubMed ID
GWAS Study Type
16112 Participants
81 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

CS
Choi SH
RD
Ruggiero D
SR
Sorice R
SC
Song C
NT
Nutile T
VS
Vernon Smith A
CM
Concas MP
TM
Traglia M
BC
Barbieri C
NN
Ndiaye NC
SM
Stathopoulou MG
LV
Lagou V
MG
Maestrale GB
SC
Sala C
DS
Debette S
KP
Kovacs P
LL
Lind L
LJ
Lamont J
FP
Fitzgerald P
TA
Tönjes A
GV
Gudnason V
TD
Toniolo D
PM
Pirastu M
BC
Bellenguez C
VR
Vasan RS
IE
Ingelsson E
LA
Leutenegger AL
JA
Johnson AD
DA
DeStefano AL
VS
Visvikis-Siest S
SS
Seshadri S
CM
Ciullo M
Chapter II

Abstract

Summary of the research findings

Vascular endothelial growth factor (VEGF) is an angiogenic and neurotrophic factor, secreted by endothelial cells, known to impact various physiological and disease processes from cancer to cardiovascular disease and to be pharmacologically modifiable. We sought to identify novel loci associated with circulating VEGF levels through a genome-wide association meta-analysis combining data from European-ancestry individuals and using a dense variant map from 1000 genomes imputation panel. Six discovery cohorts including 13,312 samples were analyzed, followed by in-silico and de-novo replication studies including an additional 2,800 individuals. A total of 10 genome-wide significant variants were identified at 7 loci. Four were novel loci (5q14.3, 10q21.3, 16q24.2 and 18q22.3) and the leading variants at these loci were rs114694170 (MEF2C, P = 6.79 x 10(-13)), rs74506613 (JMJD1C, P = 1.17 x 10(-19)), rs4782371 (ZFPM1, P = 1.59 x 10(-9)) and rs2639990 (ZADH2, P = 1.72 x 10(-8)), respectively. We also identified two new independent variants (rs34528081, VEGFA, P = 1.52 x 10(-18); rs7043199, VLDLR-AS1, P = 5.12 x 10(-14)) at the 3 previously identified loci and strengthened the evidence for the four previously identified SNPs (rs6921438, LOC100132354, P = 7.39 x 10(-1467); rs1740073, C6orf223, P = 2.34 x 10(-17); rs6993770, ZFPM2, P = 2.44 x 10(-60); rs2375981, KCNV2, P = 1.48 x 10(-100)). These variants collectively explained up to 52% of the VEGF phenotypic variance. We explored biological links between genes in the associated loci using Ingenuity Pathway Analysis that emphasized their roles in embryonic development and function. Gene set enrichment analysis identified the ERK5 pathway as enriched in genes containing VEGF associated variants. eQTL analysis showed, in three of the identified regions, variants acting as both cis and trans eQTLs for multiple genes. Most of these genes, as well as some of those in the associated loci, were involved in platelet biogenesis and functionality, suggesting the importance of this process in regulation of VEGF levels. This work also provided new insights into the involvement of genes implicated in various angiogenesis related pathologies in determining circulating VEGF levels. The understanding of the molecular mechanisms by which the identified genes affect circulating VEGF levels could be important in the development of novel VEGF-related therapies for such diseases.

9541 European ancestry individuals, 1,115 Cilento (founder/genetic isolated) individuals, 897 Ogliastran (founder/genetic isolated) individuals, 1,759 Val Borbera (founder/genetic isolated) individuals

Chapter III

Study Statistics

Key metrics and study information

16112
Total Participants
GWAS
Study Type
Yes
Replicated
2,141 European ancestry individuals, 659 Sorbian (founder/genetic isolated) individuals
Replication Participants
European
Ancestry
Germany, France, Sweden, Iceland, Italy
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.